DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Sarilumab
Sarilumab
Inflammatory Conditions – Kevzara™ (Sarilumab for Subcutaneous Injection)
Tocilizumab and Sarilumab Alone Or in Combination with Corticosteroids For
Sarilumab-Kevzara-Fact-Sheet.Pdf
“Drug Lag” Analysis of Monoclonal Antibodies in the United States and Europe
Immune Modulating Therapies for Rheumatologic, Dermatologic and Gastrointestinal Diseases
Sarilumab for Moderate to Severe Rheumatoid Arthritis
Downloads/Drugs/Developmentapprovalprocess/Howdrugsa 96
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
2017 New Drug Update
Schedule 14A
Information for Hospitalised Patients About Tocilizumab/ Sarilumab for the Treatment of Covid-19 Infection
Press Release Source: Sanofi (EURONEXT: SAN) (NASDAQ: SNY)
KEVZARA (Sarilumab) Injection, for Subcutaneous Use ------CONTRAINDICATIONS------ Initial U.S
Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
CDER List of Licensed Biological Products With
(INN) for Biological and Biotechnological Substances
Kevzara (Sarilumab)
Anti-IL6R: Tocilizumab, Satralizumab, Sarilumab, Olokizumab, Vobarilizumab Anti-IL6: Siltuximab, Sirukumab, Clazakizumab
Top View
COVID-19 Therapeutic Alert
How KEVZARA® (Sarilumab) Works
Lumicera Specialty Drug List
WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
1626.Full.Pdf
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
Immunmoduláció, Immunszuppresszió)
761037Orig1s000
As a Treatment Type for COVID-19
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Interim Position Statement: Interleukin-6 Inhibitors (Tocilizumab Or Sarilumab) for Patients Admitted to ICU with COVID-19 Pneum
New Drug Evaluation Monograph Template
Regeneron and Sanofi Announce Sarilumab Biologics License Application Accepted for Review by US FDA
Download the PDF Version
Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: an Overview
Sarilumab | Memorial Sloan Kettering Cancer Center
Inflammatory Conditions – Tremfya® (Guselkumab for Subcutaneous Injection)
Reimbursement Criteria for Frequently Requested Drugs
Download the PDF Version
Chromatin Interactions Reveal Novel Gene Targets for Drug Repositioning
A Randomised Phase II Study Evaluating the Efficacy and Safety Of
Inflammatory Conditions – Taltz® (Ixekizumab for Subcutaneous Injection)
Tocilizumab and Sarilumab for Patients with Covid-19 Pneumonia (Adults)
WHO Drug Information Vol
Az Immunfarmakológia Alapjai És Immuntoxikológia
COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases
Susceptibility and Severity of COVID-19 in Patients Treated With
Self-Administered Medications List
Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
DRAFT COMPARISON of the WHO ATC CLASSIFICATION & Ephmra
Systematic Review and Meta-Analysis of Anakinra, Sarilumab, Siltuximab and Tocilizumab for COVID-19
Axialspa-Guideline-2019.Pdf
(INN) for Biological and Biotechnological Substances
(Kevzara®) SMC No 1314/18 Sanofi Genzyme
Evaluation of the Efficacy and Safety of Sarilumab Combination Therapy In
20.201 Mechanisms of Drug Actions Sarilumab Case Study
761037Orig1s000
Sarilumab (Rch) Sanofi-Aventis Australia Pty Ltd PM-2017-03119-1-3 Final 8 April 2019
Immune Modulating Therapies for Rheumatologic, Dermatologic and Gastrointestinal Diseases
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Joint Guidelines for the Management of Interruption of Biologic Therapies for Elective Surgery in Adults and Children with Rheum
Kevzara (Sarilumab)
Cytokine and CAM Antagonists
Ocular Side Effects of Antirheumatic Medications: a Qualitative Review
Risk of Infection Associated with Biological Agents Used for Autoimmune Inflammatory Diseases
Sarilumab for the Treatment of Covid-19
Sarilumab More Effective Than Adalimumab
Antibodies to Watch in 2018